The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1600
ISSUE1600
June 15, 2020
Drugs for Atopic Dermatitis
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Drugs for Atopic Dermatitis
June 15, 2020 (Issue: 1600)
Atopic dermatitis (AD; also known as eczema) is
frequently associated with other atopic disorders
such as allergic rhinitis, asthma, and food allergy. It
commonly presents in infancy and early childhood
and has a relapsing course, often improving...more
- W Frazier and N Bhardwaj. Atopic dermatitis: diagnosis and treatment. Am Fam Physician 2020; 101:590.
- R Tanei. Atopic dermatitis in older adults: a review of treatment options. Drugs & Aging 2020; 37:149.
- EJ van Zuuren et al. Emollients and moisturisers for eczema. Cochrane Database Syst Rev 2017; 2:CD012119.
- JR Chalmers et al. Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial. Lancet 2020; 395:962.
- L Davallow Gahar et al. Low risk of adrenal insufficiency after use of low- to moderate-potency topical corticosteroids for children with atopic dermatitis. Clin Pediatr (Phila) 2019; 58:406.
- EC Siegfried et al. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr 2016; 16:75.
- LF Eichenfield et al. Guidelines of care for the management of atopic dermatitis: section 2. management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 2014; 71:116.
- JA Broeders et al. Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: a 15-year experience. J Am Acad Dermatol 2016; 75:410.
- J Castellsague et al. A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitiudinal Lymphoma and Skin Cancer Evaluation – JOELLE study). Clin Epidemiol 2018; 10:299.
- Crisaborole (Eucrisa) for atopic dermatitis. Med Lett Drugs Ther 2017; 59:34.
- AS Paller et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 2016; 75:494.
- A Ahmed et al. Magnitude of benefit for topical crisaborole in the treatment of atopic dermatitis in children and adults does not look promising: a critical appraisal. Br J Dermatol 2018; 178:659.
- LF Eichenfield et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol 2017; 77:641.
- J Schlessinger et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to <24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1). Am J Clin Dermatol 2020; 21:275.
- R Sidbury et al. Guidelines of care for the management of atopic dermatitis: section 3. management and treatment with phototherapy and systemic agents. J Am Acad Dermatol 2014; 71:327.
- FM Garritsen et al. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. Br J Dermatol 2014; 170:501.
- M Boguniewicz et al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol Pract 2017; 5:1519.
- EW Seger et al. Relative efficacy of systemic treatments for atopic dermatitis. J Am Acad Dermatol 2019; 80:411.
- Dupilumab (Dupixent) for moderate to severe atopic dermatitis. Med Lett Drugs Ther 2017; 59:64.
- EL Simpson et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016; 375:2335.
- EL Simpson et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol 2020; 156:44.
- A Blauvelt et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet 2017; 389:2287.
- M de Bruin-Weller et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol 2018; 178:1083.
- CA Utine et al. Ocular surface disease associated with dupilumab treatment for atopic diseases. Ocul Surf 2020 May 18 (epub).
- Z Ou et al. Adverse events of dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis. Int Immunopharmacol 2018; 54:303.
- A Soria et al. Development or exacerbation of head and neck dermatitis in patients treated for atopic dermatitis with dupilumab. JAMA Dermatol 2019; 155:1312.
- J Schmitt et al. Prednisolone vs. ciclosporin for severe adult eczema. An investigator-initiated double-blind placebo-controlled multicentre trial. Br J Dermatol 2010; 162:661.
- AM Drucker et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol 2020 Apr 22 (epub).
- C Goujon et al. Methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis: a phase III randomized noninferiority trial. J Allergy Clin Immunol Pract 2018; 6:562.
- ME Schram et al. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol 2011; 128:353.
- K Phan and SD Smith. Mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis. J Dermatolog Treat 2019 Aug 1 (epub).
- AM Drucker et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol 2018; 178:768.
- U Matterne et al. Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema. Cochrane Database Syst Rev 2019; 1:CD012167.
- M Napolitano et al. Profile of baricitinib and its potential in the treatment of moderate to severe atopic dermatitis: a short review on the emerging clinical evidence. J Asthma Allergy 2020; 13:89.
- E Guttman-Yassky et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol 2020; 145:877.
- AM Montilla et al. Scoping review on the use of drugs targeting JAK/STAT pathway in atopic dermatitis, vitiligo, and alopecia areata. Dermatol Ther (Heidelb) 2019; 9:655.
- D Deleanu and I Nedelea. Biological therapies for atopic dermatitis: an update (review). Exp Ther Med 2019; 17:1061.
- E Guttman-Yassky et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol 2020; 156:411.
- JI Silverberg et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol 2020; 145:173.
- M Abrouk et al. Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses. J Am Acad Dermatol 2017; 77:177.
- Drugs for irritable bowel syndrome. Med Lett Drugs Ther 2020; 62:41.
- A Makrgeorgou et al. Probiotics for treating eczema. Cochrane Database Syst Rev 2018; 11:CD006135.
- P Rizk et al. Allergen immunotherapy and atopic dermatitis: the good, the bad, and the unknown. Curr Allergy Asthma Rep 2019; 19:57.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Atopic Dermatitis
Article code: 1600a
Article code: 1600a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.